Drug Profile
Research programme: BACE1 protein inhibitors - AbbVie/Boehringer Ingelheim
Alternative Names: BACE1 inhibitors - AbbVie; Beta secretase inhibitors - Allergan; BI 1147560; VTP 36951Latest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator Vitae Pharmaceuticals
- Developer AbbVie; Boehringer Ingelheim
- Class Small molecules
- Mechanism of Action BACE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
- 27 Jul 2015 Vitae Pharmaceuticals and Boehringer Ingelheim to end collaboration and license agreement for BACE inhibitors